Fecal Microbiota Transplantation as an Effective Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection in a Renal Transplant Patient

References

• Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707.23034326
   PubMed Web of Science ®Google Scholar
• van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–120. doi:10.1016/j.diagmicrobio.2012.11.00923290507
   PubMed Web of Science ®Google Scholar
• Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43(8):4178–4182. doi:10.1128/JCM.43.8.4178-4182.200516081970
   PubMed Web of Science ®Google Scholar
• Shon AS, Bajwa RP, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013;4(2):107–118. doi:10.4161/viru.2271823302790
   PubMed Web of Science ®Google Scholar
• Fecal Microbiota Transplantation-standardization Study Group. Nanjing consensus on methodology of washed microbiota transplantation. Chin Med J. 2020.
   Web of Science ®Google Scholar
• Dai M, Liu Y, Chen W, et al. Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients. Crit Care. 2019;23(1):324. doi:10.1186/s13054-019-2604-531639033
   PubMed Web of Science ®Google Scholar
• Zhang T, Lu G, Zhao Z, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. Protein Cell. 2020;11:251–266. doi:10.1007/s13238-019-00684-831919742
   PubMed Web of Science ®Google Scholar
• Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17‐24. doi:10.1016/S2468-1253(17)30338-2
   Web of Science ®Google Scholar
• Aroniadis OC, Brandt LJ, Oneto C, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2019;4(9):675–685. doi:10.1016/S2468-1253(19)30198-031326345
   PubMed Web of Science ®Google Scholar
• Orenstein R, Dubberke E, Hardi R, et al.; PUNCH CD Investigators. Safety and durability of RBX2660 (Microbiota suspension) for recurrent clostridium difficile infection: results of the PUNCH CD Study. Clin Infect Dis. 2016;62(5):596–602. doi:10.1093/cid/civ93826565008
   PubMed Web of Science ®Google Scholar
• Grosen AK, Povlsen JV, Lemming LE, Jørgensen SMD, Dahlerup JF, Hvas CL. Klebsiella pneumoniae faecal microbiota transplantation eradicated extended-spectrum beta-lactamase-producing from a renal transplant recipient with recurrent urinary tract infections. Case Rep Nephrol Dialysis. 2019;9(2):102–107. doi:10.1159/000502336
   PubMed Web of Science ®Google Scholar
• Bengoechea JA, Sa Pessoa J. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2019;43(2):123–144. doi:10.1093/femsre/fuy04330452654
   PubMed Web of Science ®Google Scholar
• Pogue JM, Ortwine JK, Kaye KS. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? Int J Antimicrob Agents. 2016;48:622–626. doi:10.1016/j.ijantimicag.2016.11.00127876274
   PubMed Web of Science ®Google Scholar
• Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol. 2016;80(3):629–661.
   PubMed Web of Science ®Google Scholar
• Siu LK, Yeh KM, Lin JC, Fung CP, Chang FY. Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect Dis. 2012;12(11):881–887. doi:10.1016/S1473-3099(12)70205-023099082
   PubMed Web of Science ®Google Scholar
• Tu YC, Lu MC, Chiang MK, et al. Genetic requirements for Klebsiella pneumoniae-induced liver abscess in an oral infection model. Infect Immun. 2009;77(7):2657–2671. doi:10.1128/IAI.01523-0819433545
   PubMed Web of Science ®Google Scholar
• Gabe SM, Bjarnason I, Tolou-Ghamari Z, et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology. 1998;115(1):67–74. doi:10.1016/S0016-5085(98)70366-X9649460
   PubMed Web of Science ®Google Scholar
• Khanna S, Vazquez-Baeza Y, Gonzalez A, et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome. 2017;5(1):55. doi:10.1186/s40168-017-0269-328506317
   PubMed Web of Science ®Google Scholar
• Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Malagelada JR. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut. 2001;48(4):503–507. doi:10.1136/gut.48.4.50311247894
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. Dig Dis. 2015;33:338–345. doi:10.1159/00037167826045267
   PubMed Web of Science ®Google Scholar
• Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe. 2014;16(6):770–777. doi:10.1016/j.chom.2014.11.00325498344
   PubMed Web of Science ®Google Scholar
• Fernández-Veledo S, Vendrell J. Gut microbiota-derived succi-nate: friend or for in human metabolic diseases? Rev Endocr Metab Disord. 2019;20(4):439–447. doi:10.1007/s11154-019-09513-z31654259
   PubMed Web of Science ®Google Scholar